Navellier & Associates Inc. grew its position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 123.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 257,142 shares of the biotechnology company's stock after purchasing an additional 142,206 shares during the quarter. Navellier & Associates Inc. owned approximately 0.19% of Aurinia Pharmaceuticals worth $4,364,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in AUPH. BOK Financial Private Wealth Inc. bought a new position in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $32,000. Global Retirement Partners LLC bought a new stake in Aurinia Pharmaceuticals during the 2nd quarter worth approximately $41,000. Quantbot Technologies LP bought a new stake in Aurinia Pharmaceuticals during the 2nd quarter worth approximately $45,000. Allworth Financial LP acquired a new position in Aurinia Pharmaceuticals in the 2nd quarter valued at approximately $56,000. Finally, Frazier Financial Advisors LLC increased its position in Aurinia Pharmaceuticals by 411.9% in the 1st quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company's stock valued at $51,000 after acquiring an additional 2,793 shares during the period. 36.83% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other news, CEO Kevin Tang acquired 206,005 shares of Aurinia Pharmaceuticals stock in a transaction on Tuesday, June 2nd. The stock was purchased at an average price of $15.28 per share, with a total value of $3,147,756.40. Following the completion of the purchase, the chief executive officer owned 13,044,106 shares of the company's stock, valued at approximately $199,313,939.68. The trade was a 1.60% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.40% of the company's stock.
Aurinia Pharmaceuticals Trading Down 1.2%
AUPH opened at $16.29 on Friday. Aurinia Pharmaceuticals Inc has a 1-year low of $10.34 and a 1-year high of $19.25. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07. The company has a market cap of $2.17 billion, a P/E ratio of 7.11 and a beta of 1.42. The company has a fifty day moving average price of $15.98 and a two-hundred day moving average price of $15.49.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.04. The company had revenue of $58.57 million for the quarter, compared to analysts' expectations of $80.45 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. Analysts predict that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on AUPH. Royal Bank Of Canada increased their price objective on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a "sector perform" rating in a report on Friday, August 7th. Bloom Burton raised Aurinia Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 20th. Weiss Ratings upgraded Aurinia Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday. Wall Street Zen cut Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Finally, Zacks Research downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Aurinia Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $17.67.
View Our Latest Research Report on Aurinia Pharmaceuticals
About Aurinia Pharmaceuticals
(
Free Report)
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company's proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company's lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
